Advancement of COX-2 inhibitior in breast cancer medication

Ting DENG,Chun-hong HU
DOI: https://doi.org/10.3969/j.issn.1673-2588.2006.05.005
2006-01-01
Abstract:Cyclooxygenase-2 overexpresses in breast cancer, and is related to its genesis,development and prognosis.Selective COX-2 inhibitors can combine with chemotherapy,endocrine therapy and biotherapy.It is gradually used for adjunctive therapy and provides a new pathway for the therapy of breast cancer.
What problem does this paper attempt to address?